Medifast Past Earnings Performance
Past criteria checks 0/6
Medifast's earnings have been declining at an average annual rate of -3.2%, while the Personal Products industry saw earnings growing at 9.3% annually. Revenues have been growing at an average rate of 5.3% per year. Medifast's return on equity is 3.5%, and it has net margins of 1.1%.
Key information
-3.2%
Earnings growth rate
-1.7%
EPS growth rate
| Personal Products Industry Growth | 20.9% |
| Revenue growth rate | 5.3% |
| Return on equity | 3.5% |
| Net Margin | 1.1% |
| Last Earnings Update | 30 Sep 2024 |
Recent past performance updates
Recent updates
Medifast, Inc.'s (NYSE:MED) Business And Shares Still Trailing The Industry
Dec 11
Medifast: Earnings Surprise, New AI Technologies, And Extremely Undervalued
Nov 06Medifast: Reorganization, GLP-1 Medication, And FCF Imply Undervaluation
Sep 03Medifast Business Continues To Shrink, Stock Still Risky
Aug 27Medifast: GLP-1 Fears Are Overblown, But Proof Points For Turnaround Are Still Missing
Jun 26Medifast: Significant Undervaluation Even As Struggles Persist
May 24At US$22.76, Is Medifast, Inc. (NYSE:MED) Worth Looking At Closely?
May 24Lacklustre Performance Is Driving Medifast, Inc.'s (NYSE:MED) 32% Price Drop
May 24Medifast's (NYSE:MED) Conservative Accounting Might Explain Soft Earnings
May 06The Returns On Capital At Medifast (NYSE:MED) Don't Inspire Confidence
May 01Medifast: Cheap Valuation, Uncertain Future
Mar 20Medifast Is Getting Attractive
Mar 07Medifast, Inc.'s (NYSE:MED) 26% Dip In Price Shows Sentiment Is Matching Earnings
Feb 22Medifast Share Price Loses Weight, But Is There Still Value To Be Had?
Jan 20Are Investors Undervaluing Medifast, Inc. (NYSE:MED) By 47%?
Dec 09Medifast: Good On Paper, But A Slowdown In Sales Is Very Worrisome
Nov 24Is It Too Late To Consider Buying Medifast, Inc. (NYSE:MED)?
Nov 21Medifast: Unveiling A Challenge Beyond Weight Loss Drugs
Nov 09Medifast: The Race To Weight-Loss Drugs Not Lost Yet
Oct 09Medifast: Take Advantage Of Pessimism Over Weight Loss Drugs
Aug 04Is Now An Opportune Moment To Examine Medifast, Inc. (NYSE:MED)?
Jul 26In The Murky MLM Space, Medifast Might Actually Hold Some Promise
Jul 21Estimating The Intrinsic Value Of Medifast, Inc. (NYSE:MED)
Jul 05Medifast: In Survival Mode Against Diet Pills And The Recession
Jun 14Medifast Holds Value During Headwinds
May 28Medifast Non-GAAP EPS of $3.70 beats by $1.48, revenue of $337.2M beats by $7.1M
Feb 21Medifast: A Low Earnings Multiple Despite Strong Financial Performance
Feb 07At US$117, Is Medifast, Inc. (NYSE:MED) Worth Looking At Closely?
Jan 19Medifast declares $1.64 dividend
Dec 08A Look At The Intrinsic Value Of Medifast, Inc. (NYSE:MED)
Dec 01Medifast's (NYSE:MED) Sluggish Earnings Might Be Just The Beginning Of Its Problems
Nov 10One Medifast, Inc. (NYSE:MED) Analyst Just Made A Major Cut To Next Year's Estimates
Nov 08Medifast: This High-Yield Blue Chip Dividend Stock Is A Strong Buy
Nov 06What Does Medifast, Inc.'s (NYSE:MED) Share Price Indicate?
Oct 20We Think Medifast (NYSE:MED) Can Stay On Top Of Its Debt
Sep 18Medifast declares $1.64 dividend
Sep 08Do Medifast's (NYSE:MED) Earnings Warrant Your Attention?
Sep 02Revenue & Expenses Breakdown
How Medifast makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Sep 24 | 674 | 7 | 470 | 5 |
| 30 Jun 24 | 770 | 29 | 531 | 5 |
| 31 Mar 24 | 898 | 68 | 570 | 5 |
| 31 Dec 23 | 1,072 | 99 | 645 | 5 |
| 30 Sep 23 | 1,218 | 120 | 713 | 5 |
| 30 Jun 23 | 1,373 | 133 | 796 | 4 |
| 31 Mar 23 | 1,530 | 142 | 897 | 5 |
| 31 Dec 22 | 1,599 | 144 | 951 | 5 |
| 30 Sep 22 | 1,639 | 151 | 982 | 4 |
| 30 Jun 22 | 1,662 | 157 | 999 | 4 |
| 31 Mar 22 | 1,603 | 165 | 959 | 4 |
| 31 Dec 21 | 1,526 | 164 | 907 | 4 |
| 30 Sep 21 | 1,413 | 158 | 837 | 4 |
| 30 Jun 21 | 1,271 | 150 | 745 | 4 |
| 31 Mar 21 | 1,097 | 125 | 644 | 3 |
| 31 Dec 20 | 935 | 103 | 561 | 3 |
| 30 Sep 20 | 841 | 95 | 509 | 3 |
| 30 Jun 20 | 759 | 76 | 472 | 3 |
| 31 Mar 20 | 726 | 76 | 455 | 3 |
| 31 Dec 19 | 714 | 78 | 443 | 3 |
| 30 Sep 19 | 689 | 74 | 423 | 2 |
| 30 Jun 19 | 638 | 72 | 390 | 2 |
| 31 Mar 19 | 568 | 64 | 349 | 2 |
| 31 Dec 18 | 501 | 56 | 309 | 2 |
| 30 Sep 18 | 433 | 47 | 269 | 2 |
| 30 Jun 18 | 371 | 40 | 228 | 2 |
| 31 Mar 18 | 330 | 34 | 202 | 2 |
| 31 Dec 17 | 302 | 28 | 188 | 0 |
| 30 Sep 17 | 286 | 25 | 177 | 2 |
| 30 Jun 17 | 277 | 24 | 173 | 2 |
| 31 Mar 17 | 273 | 20 | 168 | 2 |
| 31 Dec 16 | 275 | 18 | 170 | 2 |
| 30 Sep 16 | 273 | 18 | 167 | 3 |
| 30 Jun 16 | 271 | 17 | 166 | 3 |
| 31 Mar 16 | 272 | 19 | 169 | 2 |
| 31 Dec 15 | 273 | 20 | 169 | 2 |
| 30 Sep 15 | 274 | 18 | 167 | 0 |
| 30 Jun 15 | 277 | 18 | 170 | 0 |
| 31 Mar 15 | 279 | 19 | 171 | 0 |
| 31 Dec 14 | 285 | 21 | 173 | 1 |
| 30 Sep 14 | 267 | 27 | 157 | 0 |
| 30 Jun 14 | 285 | 27 | 170 | 0 |
| 31 Mar 14 | 307 | 28 | 187 | 0 |
| 31 Dec 13 | 324 | 27 | 202 | 0 |
Quality Earnings: MED has a large one-off loss of $12.5M impacting its last 12 months of financial results to 30th September, 2024.
Growing Profit Margin: MED's current net profit margins (1.1%) are lower than last year (9.8%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: MED's earnings have declined by 3.2% per year over the past 5 years.
Accelerating Growth: MED's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.
Earnings vs Industry: MED had negative earnings growth (-93.9%) over the past year, making it difficult to compare to the Personal Products industry average (-5.2%).
Return on Equity
High ROE: MED's Return on Equity (3.5%) is considered low.
Return on Assets
Return on Capital Employed
Discover strong past performing companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/22 03:23 |
| End of Day Share Price | 2024/12/20 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Medifast, Inc. is covered by 12 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Anand Vankawala | Avondale Partners |
| Kara Anderson | B. Riley Securities, Inc. |
| Scott Van Winkle | Canaccord Genuity |